Table 3 Multivariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS

Age >60 years

2.40 [0.90, 6.38]

0.08

1.75 [0.37, 8.24]

0.48

Ann Arbor stage IIIE-IVE

5.65 [1.47, 21.80]

0.01

9.55 [0.87, 104.27]

0.06

LDH above normal

2.16 [0.72, 6.48]

0.17

3.60 [0.56, 23.12]

0.18

ECOG >1

2.80 [0.93, 8.48]

0.07

3.93 [0.78, 20.02]

0.10

No. of extranodal sites >3

5.34 [1.40, 20.32]

0.01

6.81 [1.09, 42.72]

0.04

hypercalcemia

1.76 [0.36, 8.54]

0.48

6.92 [1.09, 44.01]

0.04

AP above normal

0.93 [0.29, 2.97]

0.90

0.67 [0.13, 3.38]

0.63

Multifocal bone lesions

0.35 [0.11, 1.11]

0.08

0.39 [0.08, 1.81]

0.23

Rituximab

0.16 [0.04, 0.62]

0.008

0.23 [0.03, 1.80]

0.16

Intensified chemotherapy

0.50 [0.17, 1.49]

0.21

0.62 [0.13, 2.96]

0.55

Radiotherapy

0.13 [0.04, 0.42]

0.0006

0.01 [0.0006, 0.18]

0.002